GlassScriptPhysician profile
Asia A Work
NPI 1316135684
$3,845.84
in general payments reported to CMS, 2019-2025
22 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $881 · 2022: $997 · 2023: $879 · 2024: $587 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $803.04 | 2022-2025 | Inspire |
| Csl Behring | $629.21 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Optinose US, INC. | $437.92 | 2021-2025 | |
| Genzyme Corporation | $330.54 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $251.49 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $237.70 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $186.05 | 2021-2024 | Fasenra |
| Glaxosmithkline, LLC. | $183.94 | 2022-2025 | Nucala |
| Hologic Sales and Service, LLC | $122.23 | 2022 | |
| Medtronic, INC. | $114.21 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $100.07 | 2023 | Caldolor |
| Lucid Diagnostics INC. | $91.82 | 2022 | |
| Amgen INC. | $67.36 | 2021-2024 | Tezspire |
| Lilly USA, LLC | $58.29 | 2025 | Zepbound |
| Hikma Pharmaceuticals USA | $53.95 | 2023-2024 | Ryaltris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $52.60 | 2021-2024 | Auvi-Q |
| Pfizer INC. | $45.35 | 2023-2025 | |
| Stryker Corporation | $24.00 | 2022 | |
| Alk-Abello, INC | $16.74 | 2021 | |
| Abbvie INC. | $16.46 | 2025 | |
| Verona Pharma, INC. | $13.71 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $9.16 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asia Work listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.